Ziprasidone in Children With Autism: A Pilot Study

• Status: Completed
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if the drug, ziprasidone, is effective in treating problems in adolescent associated with autism.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Drexel University College of Medicine
• Treatments: Ziprasidone

Criteria

Inclusion Criteria:

• Diagnosis of autism (DSM-IV) made by a boarded child and adolescent psychiatrist.

• Males and females.

• Aged 12 to 18 years.

• Clinical judgment that medication treatment for autism is indicated.

Exclusion Criteria:

• Major medical problems including cardiac, liver, endocrine, or renal diseases.

• History of seizure disorder or gross neurological deficit.

• Baseline QTC greater than 425 msec.

• Concomitant treatment with psychotropic medication.

• History of prior exposure to ziprasidone.